Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals has signed a manufacturing supply agreement (MSA) with Sanofi-aventis, under which Sanofi-aventis is expected to supply Oramed Pharma with specified quantities of recombinant human insulin to be used by Oramed for its clinical trials in the US.
Subscribe to our email newsletter
The commercial and external partnership within industrial affairs (CEPiA) is managing the MSA at Sanofi-avantis, which will allow Oramed Pharma to leverage sanofi-aventis’ ability and expertise regarding quality and regulatory support.
Nadav Kidron, CEO of Oramed Pharma, said: “Oramed Pharma’s oral delivery technology together with Sanofi-aventis capabilities to produce insulin on a large scale supports Oramed Pharma’s efforts to conduct clinical development of Oramed Pharma’s oral insulin capsule in the diabetes market in the US. It is very satisfying to work with such a professional company and their dedicated staff.”
Oramed Pharmaceuticals is a developer of oral delivery systems. Oramed seeks to revolutionise the treatment of diabetes through its patented product, an orally ingestible insulin capsule currently in Phase 2 clinical trials.